Wall Street analysts predict that Repligen Co. (NASDAQ:RGEN) will post $161.78 million in sales for the current fiscal quarter, according to Zacks. Seven analysts have made estimates for Repligen’s earnings. The highest sales estimate is $166.80 million and the lowest is $144.40 million. Repligen posted sales of $94.06 million in the same quarter last year, which would indicate a positive year over year growth rate of 72%. The firm is scheduled to announce its next earnings report on Thursday, November 4th.
According to Zacks, analysts expect that Repligen will report full year sales of $632.54 million for the current year, with estimates ranging from $577.30 million to $644.90 million. For the next year, analysts forecast that the company will post sales of $751.07 million, with estimates ranging from $725.00 million to $790.10 million. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Repligen.
Repligen (NASDAQ:RGEN) last posted its earnings results on Monday, July 26th. The biotechnology company reported $0.79 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.27. The company had revenue of $162.96 million during the quarter, compared to analysts’ expectations of $144.24 million. Repligen had a net margin of 19.65% and a return on equity of 9.21%. Repligen’s quarterly revenue was up 86.3% on a year-over-year basis. During the same period last year, the company posted $0.42 earnings per share.
RGEN traded up $11.11 during trading on Friday, hitting $324.21. 498,731 shares of the company traded hands, compared to its average volume of 385,048. The company has a market cap of $17.80 billion, a PE ratio of 181.12 and a beta of 0.90. The stock’s 50-day simple moving average is $263.97 and its two-hundred day simple moving average is $218.80. Repligen has a 1 year low of $138.00 and a 1 year high of $327.32.
In other news, Director Karen A. Dawes sold 4,585 shares of the firm’s stock in a transaction dated Tuesday, July 20th. The shares were sold at an average price of $202.09, for a total value of $926,582.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Ralf Kuriyel sold 4,001 shares of the firm’s stock in a transaction dated Monday, August 30th. The stock was sold at an average price of $282.13, for a total transaction of $1,128,802.13. The disclosure for this sale can be found here. Insiders have sold 52,154 shares of company stock valued at $14,144,680 in the last quarter. 1.20% of the stock is owned by company insiders.
Hedge funds have recently bought and sold shares of the stock. RPg Family Wealth Advisory LLC purchased a new position in Repligen in the 2nd quarter worth about $27,000. Creative Financial Designs Inc. ADV increased its stake in Repligen by 50.0% in the 2nd quarter. Creative Financial Designs Inc. ADV now owns 150 shares of the biotechnology company’s stock worth $30,000 after buying an additional 50 shares during the period. Itau Unibanco Holding S.A. purchased a new position in Repligen in the 2nd quarter worth about $37,000. Institutional & Family Asset Management LLC increased its stake in Repligen by 1,900.0% in the 1st quarter. Institutional & Family Asset Management LLC now owns 200 shares of the biotechnology company’s stock worth $39,000 after buying an additional 190 shares during the period. Finally, Rational Advisors LLC purchased a new position in Repligen in the 2nd quarter worth about $48,000. 83.82% of the stock is currently owned by institutional investors.
Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.
See Also: Stock Portfolio Tracker
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.